"These data indicate that i-FACTOR Peptide Enhanced Bone Graft offers significant potential benefits in fusion rates compared to allograft," said Dr. Two-level concomitant degenerative olisthesis patients saw estimated fusion rates of 63 percent with i-FACTOR compared to 18 percent with allograft. Those patients with one-level concomitant degenerative olisthesis accomplished estimated fusion rates of 40 percent with i-FACTOR compared to 21 percent with allograft.ģ. At one-year postoperative follow-up, researchers found a 50 percent fusion rate using i-FACTOR versus a 20 percent fusion rate using allograft.Ģ. The patients underwent non-instrumented lumbar posterolateral spine surgery with either i-FACTOR Peptide Enhanced Bone Graft or allograft.ġ. The study involved 98 patients aged 60 or older who suffered from lumbar spinal stenosis or concomitant degenerative olisthesis. Andersen, MD, of Middelfart Hospital in Denmark, reported results from the IVANOS study investigating Cerapedics' i-FACTOR Peptide Enhanced Bone Graft. This unique combination replicates the organic (Type I human collagen) and inorganic (calcium phosphate) components of autograft bone and creates the ideal template for new bone formation. i-FACTOR Peptide Enhanced Bone Graft is the only. 20 cutting-edge spine innovations to know | 2021 According to the company, i-Factor is the only biologic bone graft that combines the small P-15 peptide with anorganic bone mineral (ABM). Cerapedics is an ortho-biologics company focused on developing and commercializing its proprietary small peptide (P-15) technology platform.Becker's Health IT + Digital Health + RCM.
![ifactor biologics ifactor biologics](https://ryortho.com/wp-content/uploads/2015/06/NoFDA_iFactorBoneGraft_WEB.jpg)
Women's + Diversity Leadership Virtual Forum.Clinical Leadership + Pharmacy Virtual Event.Patient Experience + Marketing Virtual Forum.